Long-term observational angiographic patency and perfect patency of radial artery compared with saphenous vein or internal mammary artery in coronary bypass surgery
The Journal of Thoracic and Cardiovascular Surgery · 2024-04 · 167 (4) · 1293-1302.e4
DOI: 10.1016/j.jtcvs.2022.08.047 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024-04. Verfasst von Justin Ren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Melbourne, Melbourne, Australia. Hauptthemen laut MEDLINE: Mammary Arteries. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: It is uncertain if the long-term biological behavior of the radial artery as a conduit for coronary bypass surgery has a similar resistance to the development of atherosclerosis as for the internal mammary artery. We aimed to examine long-term angiographic patency and disease-free patency (perfect patency) for internal mammary artery, radial artery, and saphenous vein grafts. METHODS: A retrospective, single-center, individual patient cohort study of angiographic observations from patients' latest postoperative angiogram from 1997 to 2020 was performed. Analysis was per anastomosis and assessed for patency and perfect patency. A generalized linear mixed model premised upon logistic regression was used to minimize confounding bias. RESULTS: A total of 983 patients with 3064 grafts were included, with a median follow-up of 8.6 (interquartile range, 4.4-12.6) years after the operation. Multivariable analysis revealed differences for radial (patency, 86.9%; perfect patency, 86.4%) and internal mammary artery (patency, 93.9%; perfect patency, 93.5%) versus saphenous vein graft (patency, 72.8%; perfect patency, 46.2%). There were no differences between the 2 arterial conduits for patency (odds ratio, 1.40; 95% CI, 0.85-2.33; P = .189) and perfect patency (odds ratio, 1.14; 95% CI, 0.71-1.84; P = .578). If a conduit was patent, then 99.4% of radial artery, 99.6% of internal mammary artery, and 63.5% of saphenous vein graft were reported as perfectly patent. CONCLUSIONS: Radial artery and internal mammary artery had similar patency and perfect patency while both were superior to saphenous vein graft.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of Melbourne, Melbourne, Australia.
- Department of Surgery, University of Melbourne, Melbourne, Australia; Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Melbourne, Australia; Outcomes Research Consortium, Cleveland Clinic, Clevel…
- Department of Surgery, University of Melbourne, Melbourne, Australia; Department of Cardiothoracic Surgery, Royal Melbourne Hospital, Melbourne, Australia. Electronic address: Alistair.Royse@gmail.com.
Zitieren
APA
Ren, J., Royse, C., Siderakis, C., Srivastav, N., & Royse, A. (2024). Long-term observational angiographic patency and perfect patency of radial artery compared with saphenous vein or internal mammary artery in coronary bypass surgery. The Journal of Thoracic and Cardiovascular Surgery, 167(4), 1293-1302.e4. https://doi.org/10.1016/j.jtcvs.2022.08.047
Vancouver
Ren J, Royse C, Siderakis C, Srivastav N, Royse A. Long-term observational angiographic patency and perfect patency of radial artery compared with saphenous vein or internal mammary artery in coronary bypass surgery. The Journal of Thoracic and Cardiovascular Surgery. 2024;167(4):1293-1302.e4. doi:10.1016/j.jtcvs.2022.08.047
BibTeX
@article{Ren2024,
author = {Ren, Justin and Royse, Colin and Siderakis, Christopher and Srivastav, Nilesh and Royse, Alistair},
title = {Long-term observational angiographic patency and perfect patency of radial artery compared with saphenous vein or internal mammary artery in coronary bypass surgery},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2024},
volume = {167},
number = {4},
pages = {1293--1302.e4},
doi = {10.1016/j.jtcvs.2022.08.047}
}
EUVIMED